TLDRSarepta Therapeutics announces January 26 release of 3-year EMBARK study data for Elevidys gene therapy at 8.30 am ET Stock dropped 3% to $21.13 Friday but surged 5% after hours to $22.20 on the announcement FDA restricted Elevidys... .
NEW YORK, Nov ... ("Sarepta" or the "Company") (NASDAQ. SRPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980 ... [Click here for information about joining the class action] ... 7980 ... 21% ... .